2 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Remix Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of REM-422 in Patients With AML or Higher Risk MDS REM-422 - Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes | Phase 1 | Recruiting | Remix Therapeutics | 100 | 2024-04-26 | 2025-04-23 |
| Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma REM-422 - Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma | Phase 1 / Phase 2 | Recruiting | Remix Therapeutics | 125 | 2023-12-20 | 2026-06-24 |
Carcinoma, Adenoid Cystic (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1)
France (2) · United States (2)